|
Tafolecimab Combined With Chemoimmunotherapy as Neoadjuvant Treatment for pMMR/MSS Locally Advanced Colon Cancer
RECRUITINGPhase 2Sponsored by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Actively Recruiting
PhasePhase 2
SponsorDaping Hospital and the Research Institute of Surgery of the Third Military Medical University
Started2026-09-20
Est. completion2029-09-20
Eligibility
Age18 Years – 80 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07840677
Summary
This multicenter, randomized, open-label, blinded-endpoint Phase II trial assesses the efficacy and safety of tolecizumab (PCSK9 inhibitor) plus sintilimab/CapeOX chemoimmunotherapy as neoadjuvant treatment for pMMR/MSS locally advanced colon adenocarcinoma .
Eligibility
Age: 18 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria: * Signed the written informed consent form and voluntarily participate in the study. * Pathohistologically confirmed colon adenocarcinoma with cT3c stage or above. * Aged 18 to 80 years, regardless of gender. * The lower edge of the tumor is more than 10 cm from the anus. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Sufficient bone marrow, liver, kidney and coagulation functions assessed by laboratory tests (in accordance with the local laboratory reference range). * No previous anti-tumor treatment for the current colon cancer (including radiotherapy, chemotherapy, surgery, etc.). * No pregnancy or lactation for female patients; male patients agree to take effective contraceptive measures during the study. Exclusion Criteria: * Previous anti-tumor treatment for the current colon cancer. * Previous use of PCSK9 inhibitors or PD-1/PD-L1 inhibitors. * Active autoimmune diseases or a history of autoimmune diseases. * Receiving immunosuppressant or systemic glucocorticoid therapy (except for local low-dose glucocorticoid use). * Active infection requiring systemic anti-infective treatment. * Severe cardiovascular diseases (e.g., severe hypertension, myocardial infarction, heart failure, etc.). * Fasting LDL-C \<1.0 mmol/L (39 mg/dL), only excluding extremely low levels (suggestive of cachexia/severe hepatic disease) * Complicated primary tumor (e.g., tumor perforation, intestinal obstruction without relief after intervention). * Pregnant or lactating women. * Other conditions that the investigator deems unfit for participation in the study (e.g., poor compliance, severe organ dysfunction, etc.).
Conditions4
CancerColon CancerNeoadjuvant ImmunochemotherapyPCSK9 Inhibitor
Interventions2
Related trials
- A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma — Fudan University
- A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC — Zhejiang Cancer Hospital
- A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS) — Shanghai Chest Hospital
- A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer — Tianjin Medical University Cancer Institute and Hospital
- A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer — The First Affiliated Hospital with Nanjing Medical University
- A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood — Second Affiliated Hospital, Zhejiang University, School of Medicine
- A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy. — Jinghui Wang
- A Single-arm, Phase II Exploratory Study of Sintilimab in Combination With Chemoradiotherapy in Elderly Patients With Locally Advanced Gastric Cancer — The First Affiliated Hospital with Nanjing Medical University
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 2
SponsorDaping Hospital and the Research Institute of Surgery of the Third Military Medical University
Started2026-09-20
Est. completion2029-09-20
Eligibility
Age18 Years – 80 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07840677